Warning: The NCBI web site requires JavaScript to function. more...
Review of Australian health economic evaluation - 245 interventions: what can we say about cost effectiveness?
Dalziel K, Segal L, Mortimer D.
Cost Eff Resour Alloc. 2008 May 20;6:9.
Related citations
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J, Jones J, Takeda A, Davidson P, Price A.
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.
Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.
Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
Griebsch I, Coast J, Brown J.
Pediatrics. 2005 May;115(5):e600-14. Review.
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.
Connock M, Burls A, Frew E, Fry-Smith A, Juarez-Garcia A, McCabe C, Wailoo A, Abrams K, Cooper N, Sutton A, O'Hagan A, Moore D.
Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. Review.
When does quality-adjusting life-years matter in cost-effectiveness analysis?
Chapman RH, Berger M, Weinstein MC, Weeks JC, Goldie S, Neumann PJ.
Health Econ. 2004 May;13(5):429-36. Review.
Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.
Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.
Cost-effectiveness analysis of humanitarian relief interventions: visceral leishmaniasis treatment in the Sudan.
Griekspoor A, Sondorp E, Vos T.
Health Policy Plan. 1999 Mar;14(1):70-6.
Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P, Jones R, Paisley S, Carroll C.
Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. Review.
The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.
Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg AJ.
Health Technol Assess. 2009 Sep;13(41):1-190, 215-357, iii-iv. Review.
Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.
Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM.
Health Technol Assess. 2004 May;8(21):iii-iv, 1-182. Review.
Global cost-effectiveness of cataract surgery.
Lansingh VC, Carter MJ, Martens M.
Ophthalmology. 2007 Sep;114(9):1670-8. Epub 2007 Mar 26.
The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A.
Health Technol Assess. 2006 Jan;10(1):iii-iv, ix-xi, 1-160. Review.
Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY, Ko SK, Liew D.
Clin Ther. 2009 Dec;31(12):2919-30; discussion 2916-8.
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL, Figgitt DP.
Pharmacoeconomics. 2004;22(6):389-411. Review.
A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1.
Connock M, Juarez-Garcia A, Frew E, Mans A, Dretzke J, Fry-Smith A, Moore D.
Health Technol Assess. 2006 Jun;10(20):iii-iv, ix-113. Review.
Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes.
Diabetes Prevention Program Research Group.
Diabetes Care. 2003 Sep;26(9):2518-23.
Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.
Green C, Dinnes J, Takeda A, Shepherd J, Hartwell D, Cave C, Payne E, Cuthbertson BH.
Health Technol Assess. 2005 Mar;9(11):1-126, iii-iv.
Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis.
Gillies CL, Lambert PC, Abrams KR, Sutton AJ, Cooper NJ, Hsu RT, Davies MJ, Khunti K.
BMJ. 2008 May 24;336(7654):1180-5. Epub 2008 Apr 21.
Clinical effectiveness and cost-effectiveness of laparoscopic surgery for colorectal cancer: systematic reviews and economic evaluation.
Murray A, Lourenco T, de Verteuil R, Hernandez R, Fraser C, McKinley A, Krukowski Z, Vale L, Grant A.
Health Technol Assess. 2006 Nov;10(45):1-141, iii-iv. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on